巴瑞替尼对比阿达木单抗、托珠单抗和托法替布单药治疗对疼痛与躯体功能改善的匹配调整间接比较
该研究采用匹配调整间接比较(MAIC)方法,基于随机、甲氨蝶呤对照的III期试验数据,比较巴瑞替尼、阿达木单抗、托珠单抗和托法替布单药治疗在csDMARDs/bDMARD初治RA患者中6个月时疼痛和躯体功能的改善。结果显示巴瑞替尼在疼痛和HAQ-DI改善上优于阿达木单抗和托珠单抗(p<0.05),而与托法替布无显著差异。
要点
- 巴瑞替尼单药在6个月时疼痛和HAQ-DI改善优于阿达木单抗和托珠单抗(p<0.05)。
- 巴瑞替尼与托法替布在疼痛和HAQ-DI改善上无显著差异。
- MAIC方法中,巴瑞替尼对比阿达木单抗的疼痛VAS疗效差为-12(三种方法一致)。
核心结论
- 在csDMARDs/bDMARD初治RA患者中,巴瑞替尼单药治疗6个月时疼痛和躯体功能改善优于阿达木单抗和托珠单抗单药治疗。
- 巴瑞替尼与托法替布单药治疗在疼痛和HAQ-DI改善上无统计学显著差异。
研究设计与样本
- 匹配调整间接比较(MAIC),数据来源于巴瑞替尼、托珠单抗、阿达木单抗、托法替布或甲氨蝶呤单药治疗的III期随机对照试验。
- 采用治疗臂匹配MAIC、研究水平匹配MAIC和不匹配的Bucher法比较各治疗间结局变化。
- 匹配变量包括年龄、性别、基线疾病活动度和结局指标的基线值。
主要发现
- 巴瑞替尼对比阿达木单抗的疼痛VAS疗效差(治疗臂匹配、研究水平匹配、Bucher法)分别为-12、-12、-12。
- 巴瑞替尼对比托珠单抗的疼痛VAS疗效差分别为-7、-7、-9。
- 巴瑞替尼对比阿达木单抗的HAQ-DI疗效差分别为-0.28、-0.28、-0.30。
- 巴瑞替尼对比托珠单抗的HAQ-DI疗效差分别为-0.23、-0.23、-0.26。
- 巴瑞替尼对比托法替布:疼痛改善仅Bucher法显示统计学显著差异,HAQ-DI无显著差异。
关键数值与推荐
- 疼痛采用视觉模拟量表(0-100 mm)评估,躯体功能采用健康评估问卷-残疾指数(HAQ-DI)评估。
- 所有方法均显示巴瑞替尼对比阿达木单抗和托珠单抗在疼痛和HAQ-DI改善上p<0.05。
临床怎么用
- 对于csDMARDs/bDMARD初治的RA患者,巴瑞替尼单药可能在疼痛和躯体功能改善上优于阿达木单抗和托珠单抗单药。
- 巴瑞替尼与托法替布单药在疼痛和躯体功能改善上疗效相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare improvement in pain and physical function for patients treated with baricitinib, adalimumab, tocilizumab and tofacitinib monotherapy from randomised, methotrexate (MTX)-controlled trials in conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)/biologic (bDMARD)-naïve RA patients using matching-adjusted indirect comparisons (MAICs). METHODS: Data were from Phase III trials on patients receiving monotherapy baricitinib, tocilizumab, adalimumab, tofacitinib or MTX. Pain was assessed using a visual analogue scale (0-100 mm) and physical function using the Health Assessment Questionnaire-Disability Index (HAQ-DI). An MAIC based on treatment-arm matching, an MAIC with study-level matching and Bucher's method without matching compared change in outcomes between therapies. Matching variables included age, gender, baseline disease activity and baseline value of outcome measure. RESULTS: With all methods, greater improvements were observed in pain and HAQ-DI at 6 months for baricitinib compared with adalimumab and tocilizumab (p<0.05). Differences in treatment effects (TEs) favouring baricitinib for pain VAS for treatment-arm matching, study-level matching and Bucher's method, respectively, were -12, -12 and -12 for baricitinib versus adalimumab and -7, -7 and -9 for baricitinib versus tocilizumab; the difference in TEs for HAQ-DI was -0.28, -0.28 and -0.30 for adalimumab and -0.23, -0.23 and -0.26 for tocilizumab. For baricitinib versus tofacitinib, no statistically significant differences for pain improvement were observed except with one of the three methods (Bucher method) and none for HAQ-DI. CONCLUSIONS: Results suggest greater pain reduction and improved physical function for baricitinib monotherapy compared with tocilizumab and adalimumab monotherapy. No statistically significant differences in pain reduction and improved physical function were observed between baricitinib and tofacitinib with the MAIC analyses.
引用
- Fautrel B, Zhu B, Taylor PC, et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open. 2020. PMID: 32371431. doi:10.1136/rmdopen-2019-001131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。